Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alastair Greystoke

Showing results (1-10 of 90) with videos related to

Pageof 9
Sort By:
The Lancet. Healthy Longevity|September 13, 2022
Is it time to move on to the next generation of clinical trials in older patients with cancer?Hannah Lowe, Alastair Greystoke
Drug Discovery Today|August 9, 2015
An introduction to stratified medicineAlastair Greystoke, Anshuman Chaturvedi
Cancer Treatment and Research Communications|December 11, 2025
Illuminating the spectrum of genomic sequencing approaches in the precision oncology era: A UK perspectivePasquale Rescigno, Alastair Greystoke
Biomarkers in Medicine|October 7, 2015
The use of circulating biomarkers in early clinical trials in patients with cancerManolo D'Arcangelo, Jane Margetts, Alastair Greystoke
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|June 21, 2020
Hypofractionated chemoradiotherapy for locally advanced non-small cell lung cancer: Is split-dose chemotherapy safer than full dose chemotherapy?Muhammad Shahid Iqbal, Rhona McMenemin, Alastair Greystoke
Experimental Cell Research|April 10, 2012
Biomarkers of cell death applicable to early clinical trialsEmma Dean, Alastair Greystoke, Malcolm Ranson, et al.
British Journal of Cancer|December 9, 2020
Practical implications to contemplate when considering radical therapy for stage III non-small-cell lung cancerClaire L Storey, Gerard G Hanna, Alastair Greystoke, et al.
Immunotherapy|November 26, 2024
Avoided recurrences and costs with adjuvant atezolizumab for patients with early non-small cell lung cancer in EuropeAlastair Greystoke, Nick Jovanoski, Pavel Napalkov, et al.
Pathologie-Biologie|March 21, 2006
Update on tubulin-binding agentsGerhardt Attard, Alastair Greystoke, Stan Kaye, et al.
Journal of Epidemiology and Community Health|June 30, 2026
Sociodemographic inequalities in non-small cell lung cancer (NSCLC) novel treatments: a national population-based cohort studySarah Rae, Erin Pennock, Adam Todd, et al.
Pageof 9

Showing results (1-10 of 90) with videos related to

Sort By:
Pageof 9
The Lancet. Healthy Longevity|September 13, 2022
Is it time to move on to the next generation of clinical trials in older patients with cancer?Hannah Lowe, Alastair Greystoke
Drug Discovery Today|August 9, 2015
An introduction to stratified medicineAlastair Greystoke, Anshuman Chaturvedi
Cancer Treatment and Research Communications|December 11, 2025
Illuminating the spectrum of genomic sequencing approaches in the precision oncology era: A UK perspectivePasquale Rescigno, Alastair Greystoke
Biomarkers in Medicine|October 7, 2015
The use of circulating biomarkers in early clinical trials in patients with cancerManolo D'Arcangelo, Jane Margetts, Alastair Greystoke
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|June 21, 2020
Hypofractionated chemoradiotherapy for locally advanced non-small cell lung cancer: Is split-dose chemotherapy safer than full dose chemotherapy?Muhammad Shahid Iqbal, Rhona McMenemin, Alastair Greystoke
Experimental Cell Research|April 10, 2012
Biomarkers of cell death applicable to early clinical trialsEmma Dean, Alastair Greystoke, Malcolm Ranson, et al.
British Journal of Cancer|December 9, 2020
Practical implications to contemplate when considering radical therapy for stage III non-small-cell lung cancerClaire L Storey, Gerard G Hanna, Alastair Greystoke, et al.
Immunotherapy|November 26, 2024
Avoided recurrences and costs with adjuvant atezolizumab for patients with early non-small cell lung cancer in EuropeAlastair Greystoke, Nick Jovanoski, Pavel Napalkov, et al.
Pathologie-Biologie|March 21, 2006
Update on tubulin-binding agentsGerhardt Attard, Alastair Greystoke, Stan Kaye, et al.
Journal of Epidemiology and Community Health|June 30, 2026
Sociodemographic inequalities in non-small cell lung cancer (NSCLC) novel treatments: a national population-based cohort studySarah Rae, Erin Pennock, Adam Todd, et al.
Pageof 9